drugset / Trial / NCT03362060
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Phase 1
Active not recruiting
20 enrolled
Massachusetts General Hospital
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying immunotherapy as a possible treatment for metastatic Triple Negative Breast Cancer (TNBC) in participants who are HLA-A2+. The drugs involved in this study are: * PVX-410 * Pembrolizumab * Hiltonol * Montanide
Timeline
- Start
- 2017-12-12
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PVX-410 | Vaccine | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |